Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

To assess the safety and efficacy of romiplostim, a peptibody that increases platelet production, for treatment of thrombocytopenic patients with myelodysplastic syndromes (MDS). Eligible patients had lower-risk MDS (International Prognostic Scoring System low or intermediate 1), a mean baseline pla...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2010-01, Vol.28 (3), p.437-444
Hauptverfasser:	KANTARJIAN, Hagop, FENAUX, Pierre, SHAMMO, Jamile, SIEGEL, Robert, KUOLUNG HU, FRANKLIN, Janet, BERGER, Dietmar P, SEKERES, Mikkael A, BECKER, Pamela S, BORUCHOV, Adam, BOWEN, David, HELLSTROM-LINDBERG, Eva, LARSON, Richard A, LYONS, Roger M, MUUS, Petra
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biological and medical sciences Female Hematologic Agents - therapeutic use Hematologic and hematopoietic diseases Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medicin och hälsovetenskap Middle Aged Myelodysplastic Syndromes - complications Myelodysplastic Syndromes - drug therapy Receptors, Fc - therapeutic use Recombinant Fusion Proteins - therapeutic use Thrombocytopenia - drug therapy Thrombocytopenia - etiology Thrombopoietin - therapeutic use Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To assess the safety and efficacy of romiplostim, a peptibody that increases platelet production, for treatment of thrombocytopenic patients with myelodysplastic syndromes (MDS). Eligible patients had lower-risk MDS (International Prognostic Scoring System low or intermediate 1), a mean baseline platelet count
ISSN:	0732-183X 1527-7755 1527-7755
DOI:	10.1200/JCO.2009.24.7999